Review of case series of cutaneous vasculitis associated with drugs. Data are percentages unless otherwise indicated.
| Ekenstam, USA | Calabrese, USA | Marques, Portugal | Gyselbrecht, Belgium | Watts, UK | Sais, Spain | García-Porrúa, Spain | Gupta, India | Khetan, India | Ortiz-Sanjuán, Spain | |
|---|---|---|---|---|---|---|---|---|---|---|
| Year | 1984 | 1990 | 1995 | 1996 | 1998 | 1998 | 1999 | 2009 | 2012 | 2013 |
| Patients with CV, n | 82 | 220 | 51 | 63 | 84 | 160 | 138 | 50 | 61 | 773 |
| Skin biopsy | 100 | ND | 100 | 100 | ND | 100 | 100 | 100 | 100 | 45.7 |
| Patients with drug as a precipitating event, n | 8 | 63 | 28 | 5 | 1 | 15 | 33 | 25 | 12 | 239 |
| Antibiotics | ND | ND | ND | 80 | ND | ND | 39.4 | 16 | 16.7 | 62.3 |
| β-lactams | ND | ND | ND | 40 | ND | ND | 30.3 | ND | ND | 38.9 |
| Macrolides | ND | ND | ND | 0 | ND | ND | 6.1 | ND | ND | 3.8 |
| NSAID | ND | ND | ND | 20 | ND | ND | 33.3 | 36 | 41.6 | 10 |
| Other drugs | ND | ND | ND | 0 | ND | ND | 27.3 | 48 | 58.3 | 27.7 |
| Age, yrs, mean | ND | ND | ND | ND | ND | ND | 54 | ND | ND | 36 |
| Sex, M/F | ND | ND | ND | ND | ND | ND | 23/10 | ND | ND | 133/106 |
| Joint manifestations | ND | ND | ND | ND | ND | ND | 24.2 | ND | ND | 51 |
| GI manifestations | ND | ND | ND | ND | ND | ND | 27.3 | ND | ND | 38.1 |
| Renal involvement | ND | ND | ND | ND | ND | ND | 28 | ND | ND | 34.7 |
| Leukocytosis | ND | ND | ND | ND | ND | ND | 3 | ND | ND | 24.7 |
| Anemia | ND | ND | ND | ND | ND | ND | 4 | ND | ND | 18.8 |
| Increased ESR | ND | ND | ND | ND | ND | ND | 22 | ND | ND | 40.2 |
| Positive RF (tested*) | ND | ND | ND | ND | ND | ND | 0 (0/33) | ND | ND | 17.5 (22/126) |
| Positive ANA (tested*) | ND | ND | ND | ND | ND | ND | 0 (0/31) | ND | ND | 21.1 (27/128) |
| Low C3 and/or C4 (tested*) | ND | ND | ND | ND | ND | ND | 10.7 (3/28) | ND | ND | 8.3 (11/133) |
↵* No. positive/total no. tested. CV: cutaneous vasculitis; M: male; F: female; GI: gastrointestinal; ESR: erythrocyte sedimentation rate, RF: rheumatoid factor; ANA: antinuclear antibodies; C3: complement 3; C4: complement 4; NSAID: nonsteroidal antiinflammatory drugs; ND: not described.